NOTABLE LABS, LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.25 USD | -15.54% |
|
+31.58% | -33.86% |
Presenter SpeechMichael Rice (Executives)Thank you, good morning, and thank you all for partic...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The Company has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The Company's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
Calendar
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.25
USD
Average target price
8
USD
Spread / Average Target
+540.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -33.86% | 11.27M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- NTBL Stock
- News Notable Labs, Ltd.
- Transcript : Vascular Biogenics Ltd., Q1 2018 Earnings Call, May 17, 2018
